Lenexa, KSNCT07565090Now EnrollingIRB Ready

Sudan Virus Disease Clinical Trial in Lenexa, KS

Access cutting-edge sudan virus disease treatment through this phase 1 clinical trial at a research site in Lenexa. Study-provided care at no cost to qualified participants.

Sponsored by International AIDS Vaccine Initiative

Quick Self-Assessment

See if you qualify for this Lenexa location

Preparing your pre-screening questions…

Expert Care in Lenexa

Access sudan virus disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sudan virus disease treatment provided free

Apply for This Lenexa Location

Check if you qualify for this sudan virus disease clinical trial in Lenexa, KS

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Lenexa

    Convenient for KS residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Lenexa site if eligible
  4. 4Begin participation

About This Sudan Virus Disease Study in Lenexa

A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health.

Sponsor: International AIDS Vaccine Initiative

Who Can Participate

Inclusion Criteria

Adults in good general health
Participants who are 18 to 50 years of age
Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
In the opinion of the PI, participant understands risks and written informed consent will be obtained before any study-related procedures are performed
Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
All sexually active participants must consistently use male or female condoms with all sexual partners for 3 months following IP administration
All individuals of childbearing potential engaging in sexual activity that could lead to pregnancy must commit to use an effective method of contraception from at least 2 weeks before and continue until 3 months following receipt of vaccine/placebo
All individuals of childbearing potential must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Activities (SOA)
All participants must be willing to forgo donation of blood or any other tissues from screening onward throughout the course of the study

Exclusion Criteria

Any clinically relevant abnormality on history or examination including: history of immunodeficiency or autoimmune disease history of splenectomy history of malignancy in the past 5 years use of corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the Investigator within the previous 6 months body mass index (BMI) ≥ 35.0 kg/m2
Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the Investigator makes the participant unsuitable for participation in the study
Individuals who are pregnant or breastfeeding
Bleeding disorder that was diagnosed by a physician
Infectious disease: Confirmed HIV-1 or HIV-2 infection, chronic active hepatitis B infection, current hepatitis C infection, active syphilis, or medically diagnosed long COVID 19 Syndrome. Also excluded are participants with active, serious infections requiring parenteral antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment.
Any abnormal laboratory parameters at screening per protocol.
Receipt of live attenuated influenza vaccine within the previous 14 days, any other live attenuated vaccine within the previous 30 days or planned receipt within 30 days after vaccination with IP; or receipt of non-live attenuated vaccine within the previous 14 days or planned receipt within 14 days after vaccination with IP, including COVID-19 vaccines
Receipt of blood transfusion or blood-derived products within the previous 3 months
Prior potential exposure to Marburg Virus, or a medical history of hemorrhagic fever
Prior receipt of any VSV-vectored vaccine, any Marburg vaccine, or any vaccine containing a filovirus component. Prior receipt of monoclonal or polyclonal antibodies directed against Marburg or other filovirus in the past 12 months
Current participation in another clinical trial, within 3 months prior to enrollment.
History of severe local or systemic reactogenicity to vaccines, or severe allergy to food or medications, and/or allergy to any component of this vaccine.
Neuropsychiatric condition or substance abuse that compromises safety of the participant and precludes compliance with the protocol
Current or planned occupational (medical care, childcare) or household contact (residing in the same household) from screening through 3 months after IP administration with any individual at increased risk from exposure to a live viral vaccine including infants ≤ 1 year of age, adults ≥75 years of age, or immunocompromised individuals.
In the opinion of the PI, it is not in the best interest of the participant to participate in the trial
A history of long-term treatment (≥ 4 weeks) for arthritis
Participants currently experiencing a rash or who have a history of severe, chronic, or frequent rash will be excluded.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Lenexa?

Yes, this clinical trial (NCT07565090) has an active research site in Lenexa, KS that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sudan Virus Disease Treatment Options in Lenexa, KS

If you're searching for sudan virus disease treatment options in Lenexa, KS, this clinical trial (NCT07565090) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Lenexa research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced sudan virus disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sudan virus disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Lenexa, KS

See all ankylosing spondylitis clinical trials recruiting in Lenexa — not just this study.

Browse Ankylosing Spondylitis Trials in Lenexa →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsAll Conditions →

Ready to Join in Lenexa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Lenexa, KS